Legal & General Group
ADMS

Legal & General Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Legal & General Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,815
Closed -$8K – 3507
2020
Q1 		$8K Sell
2,815
-1,020
-27% -$4.57K ﹤0.01% 3212
2019
Q4 		$15K Hold
3,835
– – ﹤0.01% 3245
2019
Q3 		$20K Hold
3,835
– – ﹤0.01% 3140
2019
Q2 		$24K Sell
3,835
-408
-10% -$2.35K ﹤0.01% 3138
2019
Q1 		$30K Buy
4,243
+564
+15% +$5.07K ﹤0.01% 2933
2018
Q4 		$31K Hold
3,679
– – ﹤0.01% 2895
2018
Q3 		$73K Hold
3,679
– – ﹤0.01% 2601
2018
Q2 		$95K Buy
3,679
+592
+19% +$16.4K ﹤0.01% 2517
2018
Q1 		$74K Sell
3,087
-758
-20% -$23.9K ﹤0.01% 2580
2017
Q4 		$132K Sell
3,845
-612
-14% -$17.1K ﹤0.01% 2470
2017
Q3 		$93K Buy
4,457
+911
+26% +$16.7K ﹤0.01% 2689
2017
Q2 		$62K Sell
3,546
-662
-16% -$10.9K ﹤0.01% 2846
2017
Q1 		$73K Sell
4,208
-42
-1% -$716 ﹤0.01% 2724
2016
Q4 		$73K Buy
4,250
+2,555
+151% +$39.5K ﹤0.01% 2735
2016
Q3 		$27K Hold
1,695
– – ﹤0.01% 2765
2016
Q2 		$26K Hold
1,695
– – ﹤0.01% 2797
2016
Q1 		$24K Buy
+1,695
New +$28.5K ﹤0.01% 2642

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Legal & General Group's ADMS Position: Q2 2020 in Review

Legal & General Group sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 2,815 shares — an estimated $8K sold.

Legal & General Group first reported a position in ADMS in Q1 2016 and held it in 17 quarters. The position peaked at $132K in Q4 2017. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Legal & General Group reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Legal & General Group sold 2,815 Adamas Pharmaceuticals shares in Q2 2020, an estimated $8K.
  • Legal & General Group first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 17 quarters.
  • Legal & General Group's Adamas Pharmaceuticals position peaked at $132K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.